CO2020001106A2 - Agente terapéutico para fibrosis - Google Patents
Agente terapéutico para fibrosisInfo
- Publication number
- CO2020001106A2 CO2020001106A2 CONC2020/0001106A CO2020001106A CO2020001106A2 CO 2020001106 A2 CO2020001106 A2 CO 2020001106A2 CO 2020001106 A CO2020001106 A CO 2020001106A CO 2020001106 A2 CO2020001106 A2 CO 2020001106A2
- Authority
- CO
- Colombia
- Prior art keywords
- fibrosis
- therapeutic agent
- nek6
- nima
- smad2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un inhibidor de la fosforilación de la proteína SMAD2/3 o un agente terapéutico para la fibrosis que contiene como ingrediente activo un ácido nucleico que suprime la expresión génica de NEK6 (serina/treonina quinasa 6 relacionada con NIMA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017146957 | 2017-07-28 | ||
PCT/JP2018/028459 WO2019022257A1 (ja) | 2017-07-28 | 2018-07-30 | 線維症治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020001106A2 true CO2020001106A2 (es) | 2020-02-18 |
Family
ID=65041024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0001106A CO2020001106A2 (es) | 2017-07-28 | 2020-01-30 | Agente terapéutico para fibrosis |
Country Status (16)
Country | Link |
---|---|
US (1) | US11326163B2 (es) |
EP (1) | EP3659609B1 (es) |
JP (1) | JP7204649B2 (es) |
KR (1) | KR20200033927A (es) |
CN (1) | CN110996969B (es) |
AU (1) | AU2018307897B2 (es) |
BR (1) | BR112020001412A2 (es) |
CA (1) | CA3069406A1 (es) |
CL (1) | CL2020000219A1 (es) |
CO (1) | CO2020001106A2 (es) |
EA (1) | EA202090393A1 (es) |
IL (1) | IL272271A (es) |
PH (1) | PH12020500198A1 (es) |
SG (1) | SG11201913541QA (es) |
TW (1) | TW201910514A (es) |
WO (1) | WO2019022257A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3915567A4 (en) * | 2019-01-25 | 2022-09-21 | Kyorin Pharmaceutical Co., Ltd. | THERAPEUTIC AGAINST FIBROSIS |
JPWO2022045224A1 (es) | 2020-08-25 | 2022-03-03 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US20040097441A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of NIMA-related kinase 6 expression |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
WO2012005368A1 (ja) | 2010-07-08 | 2012-01-12 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
EP2639307B1 (en) * | 2010-08-03 | 2015-03-04 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
US9315799B2 (en) | 2011-05-10 | 2016-04-19 | Bonac Corporation | Process for preparing phosphate compound bearing isotope |
CN103906758B (zh) | 2011-08-25 | 2017-05-10 | 株式会社博纳克 | 配糖体化合物、硫醚的制造方法、醚、醚的制造方法、配糖体化合物的制造方法及核酸的制造方法 |
CN104039961A (zh) | 2012-01-07 | 2014-09-10 | 株式会社博纳克 | 具有氨基酸骨架的单链核酸分子 |
CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
WO2014139885A2 (en) | 2013-03-14 | 2014-09-18 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
CA2938592A1 (en) | 2014-02-07 | 2015-08-13 | Effector Therapeutics, Inc. | Methods for treating fibrotic disease |
US20180036409A1 (en) | 2014-12-29 | 2018-02-08 | Bonac Corporation | Composition containing nucleic acid molecule stably |
WO2016158809A1 (ja) | 2015-03-27 | 2016-10-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
US10377788B2 (en) | 2015-04-02 | 2019-08-13 | Bonac Corporation | Method for producing glycoside compounds |
-
2018
- 2018-07-30 EP EP18839482.9A patent/EP3659609B1/en active Active
- 2018-07-30 CN CN201880049352.2A patent/CN110996969B/zh active Active
- 2018-07-30 KR KR1020207005247A patent/KR20200033927A/ko not_active Application Discontinuation
- 2018-07-30 TW TW107126352A patent/TW201910514A/zh unknown
- 2018-07-30 EA EA202090393A patent/EA202090393A1/ru unknown
- 2018-07-30 WO PCT/JP2018/028459 patent/WO2019022257A1/ja active Application Filing
- 2018-07-30 US US16/633,909 patent/US11326163B2/en active Active
- 2018-07-30 CA CA3069406A patent/CA3069406A1/en active Pending
- 2018-07-30 SG SG11201913541QA patent/SG11201913541QA/en unknown
- 2018-07-30 JP JP2019532895A patent/JP7204649B2/ja active Active
- 2018-07-30 AU AU2018307897A patent/AU2018307897B2/en active Active
- 2018-07-30 BR BR112020001412-5A patent/BR112020001412A2/pt not_active Application Discontinuation
-
2020
- 2020-01-27 IL IL272271A patent/IL272271A/en unknown
- 2020-01-27 PH PH12020500198A patent/PH12020500198A1/en unknown
- 2020-01-27 CL CL2020000219A patent/CL2020000219A1/es unknown
- 2020-01-30 CO CONC2020/0001106A patent/CO2020001106A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN110996969A (zh) | 2020-04-10 |
EP3659609A4 (en) | 2021-04-21 |
BR112020001412A2 (pt) | 2020-08-04 |
US20210087556A1 (en) | 2021-03-25 |
CN110996969B (zh) | 2023-02-28 |
KR20200033927A (ko) | 2020-03-30 |
EA202090393A1 (ru) | 2020-05-20 |
CA3069406A1 (en) | 2019-01-31 |
PH12020500198A1 (en) | 2020-09-28 |
JPWO2019022257A1 (ja) | 2020-05-28 |
EP3659609B1 (en) | 2024-05-08 |
US11326163B2 (en) | 2022-05-10 |
JP7204649B2 (ja) | 2023-01-16 |
AU2018307897B2 (en) | 2024-01-25 |
IL272271A (en) | 2020-03-31 |
WO2019022257A1 (ja) | 2019-01-31 |
EP3659609A1 (en) | 2020-06-03 |
TW201910514A (zh) | 2019-03-16 |
CL2020000219A1 (es) | 2020-07-24 |
AU2018307897A1 (en) | 2020-01-30 |
SG11201913541QA (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002994A1 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
EA201990202A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
DOP2017000048A (es) | Compuestos aminopirimidinilo como inhibidores de jak. | |
CR20190212A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
CL2018003060A1 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
DOP2019000132A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO DE LAS MISMAS. | |
CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
BR112018006103A2 (pt) | aplicador de precisão | |
MA40902B1 (fr) | Vaccins hpv16 thérapeutiques | |
CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
BR112017004393A2 (pt) | formulações de anticorpo | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
CL2018000158A1 (es) | Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772) | |
CO2019013035A2 (es) | Heteroaril fenil aminoquinolinas y sus análogos | |
JOP20190262B1 (ar) | مثبطات بيرازول magl | |
CO2020001106A2 (es) | Agente terapéutico para fibrosis | |
BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
AR115960A1 (es) | Composiciones y métodos para inhibir la expresión del gen lect2 |